Glenmark Pharmaceuticals Limited (GLENMARK) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GLENMARK Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Glenmark

Pharmaceuticals Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GLENMARK Stock 12 Month Forecast

Average Price Target

₹2,370.00

▲(14.72% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Glenmark Pharmaceuticals Limited in the last 3 months. The average price target is ₹2,370.00 with a high forecast of ₹2,370.00 and a low forecast of ₹2,370.00. The average price target represents a 14.72% change from the last price of ₹2,065.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1274":"₹1,274","2371":"₹2,371","1548.25":"₹1,548.3","1822.5":"₹1,822.5","2096.75":"₹2,096.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2370,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.37K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2370,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.37K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2370,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.37K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1274,1548.25,1822.5,2096.75,2371],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1956.15,1987.9846153846154,2019.819230769231,2051.653846153846,2083.4884615384617,2115.3230769230768,2147.1576923076923,2178.992307692308,2210.8269230769233,2242.6615384615384,2274.496153846154,2306.3307692307694,2338.1653846153845,{"y":2370,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1956.15,1987.9846153846154,2019.819230769231,2051.653846153846,2083.4884615384617,2115.3230769230768,2147.1576923076923,2178.992307692308,2210.8269230769233,2242.6615384615384,2274.496153846154,2306.3307692307694,2338.1653846153845,{"y":2370,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1956.15,1987.9846153846154,2019.819230769231,2051.653846153846,2083.4884615384617,2115.3230769230768,2147.1576923076923,2178.992307692308,2210.8269230769233,2242.6615384615384,2274.496153846154,2306.3307692307694,2338.1653846153845,{"y":2370,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1662.62,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1689.15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1546.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1610.1,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1448.94,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1275.62,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1275.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1377.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1493.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1750.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2061.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1923.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1956.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹2,370

Average Price Target₹2,370

Lowest Price Target₹2,370

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Damayanti Kerai

HSBC

₹2,380→₹2,370

Buy

14.72%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Glenmark Pharmaceuticals Limited (GLENMARK)

Saion Mukherjee

Nomura

₹1,500

Hold

-27.39%

Downside

Reiterated

09/26/25

Nomura Sticks to Its Hold Rating for Glenmark Pharmaceuticals Limited (GLENMARK)

Abdulkader Puranwala

ICICI Securities

₹1,620→₹1,570

Sell

-24.01%

Downside

Reiterated

08/19/25

Glenmark Pharmaceuticals Limited (GLENMARK) Gets a Sell from ICICI Securities

Anshuman Gupta CFA

Investec

₹1,815→₹2,510

Buy

21.49%

Upside

Reiterated

07/25/25

Investec Sticks to Their Buy Rating for Glenmark Pharmaceuticals Limited (GLENMARK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Damayanti Kerai

HSBC

₹2,380→₹2,370

Buy

14.72%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Glenmark Pharmaceuticals Limited (GLENMARK)

Saion Mukherjee

Nomura

₹1,500

Hold

-27.39%

Downside

Reiterated

09/26/25

Nomura Sticks to Its Hold Rating for Glenmark Pharmaceuticals Limited (GLENMARK)

Abdulkader Puranwala

ICICI Securities

₹1,620→₹1,570

Sell

-24.01%

Downside

Reiterated

08/19/25

Glenmark Pharmaceuticals Limited (GLENMARK) Gets a Sell from ICICI Securities

Anshuman Gupta CFA

Investec

₹1,815→₹2,510

Buy

21.49%

Upside

Reiterated

07/25/25

Investec Sticks to Their Buy Rating for Glenmark Pharmaceuticals Limited (GLENMARK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glenmark Pharmaceuticals Limited

3 Months

xxx

Success Rate

5/5 ratings generated profit

Average Return

+13.48%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.48% per trade.

1 Year

Damayanti KeraiHSBC

Success Rate

5/5 ratings generated profit

Average Return

+22.40%

reiterated a buy rating 3 months ago

Copying Damayanti Kerai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.40% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+22.40%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +22.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GLENMARK Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GLENMARK has received 2 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. GLENMARK average Analyst price target in the past 3 months is 2,370.00.

Each month's total comprises the sum of three months' worth of ratings.

GLENMARK Financial Forecast

GLENMARK Earnings Forecast

Next quarter’s earnings estimate for GLENMARK is ₹18.70 with a range of ₹18.70 to ₹18.70. The previous quarter’s EPS was ₹21.62. GLENMARK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.

GLENMARK Sales Forecast

Next quarter’s sales forecast for GLENMARK is ₹37.43B with a range of ₹36.04B to ₹38.03B. The previous quarter’s sales results were ₹60.47B. GLENMARK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GLENMARK has Performed in-line its overall industry.

GLENMARK Stock Forecast FAQ

What is IN:GLENMARK’s average 12-month price target, according to analysts?

Based on analyst ratings, Glenmark Pharmaceuticals Limited’s 12-month average price target is 2,370.00.

What is IN:GLENMARK’s upside potential, based on the analysts’ average price target?

Glenmark Pharmaceuticals Limited has 14.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Glenmark Pharmaceuticals Limited a Buy, Sell or Hold?

Glenmark Pharmaceuticals Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Glenmark Pharmaceuticals Limited’s share price target?

The average share price target for Glenmark Pharmaceuticals Limited is 2,370.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹2,370.00 ,and the lowest forecast is ₹2,370.00. The average share price target represents 14.72% Increase from the current price of ₹2,065.95.

What do analysts say about Glenmark Pharmaceuticals Limited?

Glenmark Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Glenmark Pharmaceuticals Limited?

To buy shares of IN:GLENMARK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Glenmark Pharmaceuticals Limited (GLENMARK) Stock Forecast & Price Target

GLENMARK Analyst Ratings

GLENMARK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glenmark Pharmaceuticals Limited

GLENMARK Analyst Recommendation Trends

GLENMARK Financial Forecast

GLENMARK Earnings Forecast

GLENMARK Sales Forecast

GLENMARK Stock Forecast FAQ

Detailed List of Analyst Forecasts